Ramesh Kashi
Senior Scientific Advisor, Formerly BMS Consultant
Dr. Ramesh Kashi brings more than 35 years of experience spanning start-ups, mid-size, and large biopharma organizations, with deep expertise across all facets of biologic drug product development and manufacturing. He was involved in the development of formulations for marketed therapeutic proteins like ADVATE, KEYTRUDA and ILUMYA. Throughout his career, Ramesh played a central role in shaping early-stage development strategies for complex in-licensed biologic assets and supporting IND and BLA filings. He co-led the Scientific Advisory Board (SAB) focused on evaluating external innovations and emerging technologies in high-concentration protein formulation, stabilization, and drug delivery — fostering collaborations with leading academic institutions and specialized technology developers.
Since retiring, Ramesh remains an active voice in the field by making presentations at various scientific conferences, with keen interest in keeping up with the latest developments in next-generation of biologic modalities like multispecific antibodies, (msAbs), antibody-drug conjugates (ADCs), antibody-nucleic acid conjugates (ANCs), radioligand therapies (RLTs) etc. He continues to be passionate about contributing to the exciting frontier of developing medicines in space for the benefit of patients on earth.
Seminars
- Roundtable discussions are designed to be interactive, discursive deep dives where delegates break into smaller groups to explore a focused topic through candid, peer-led conversation. Each group will exchange experiences, challenges, and practical insights before reconvening to share key takeaways with the wider audience and with the conversation being facilitated by our seminar day leaders.
- Leveraging insights from FDA-approved Bispecific and Mult Specific Antibodies as a reference to define realistic pH ranges, protein concentrations, excipients and formulation design space from the outset
- Proactively understanding the aggregation risks and atypical stability profiles of complex formats to better anticipate and mitigate key developability challenges
- Applying a stability-first formulation strategy to support faster development by reducing the need for late-stage reformulation and streamlining overall CMC readiness
